SMARCA1 and cancer: Due to the diversity of the SWI/SNF complex structure, combination, and function, SWI/SNF mutations in cancer can use the synthetic lethal interaction mode to disturb other SWI/SNF subunits or some molecules related to function, highlighting their potential as drug development target molecules [75].